Catheterization and Cardiovascular Interventions,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 5, 2025
ABSTRACT
In
2023–2024,
there
was
a
surge
in
research
on
structural
heart
disease.
This
review
aims
to
provide
comprehensive
overview
of
the
field
for
both
general
and
interventional
cardiologists,
especially
those
with
keen
interest
interventions.
It
summarizes
most
important
randomized
controlled
trials,
meta‐analyses,
retrospective
analyses,
data
registries,
noteworthy
late‐breaking
studies
unveiled
at
prominent
cardiology
conferences.
New England Journal of Medicine,
Journal Year:
2023,
Volume and Issue:
389(21), P. 1949 - 1960
Published: Oct. 24, 2023
A
previous
analysis
in
this
trial
showed
that
among
patients
with
severe,
symptomatic
aortic
stenosis
who
were
at
low
surgical
risk,
the
rate
of
composite
end
point
death,
stroke,
or
rehospitalization
1
year
was
significantly
lower
transcatheter
aortic-valve
replacement
(TAVR)
than
replacement.
Longer-term
outcomes
are
unknown.
European Heart Journal,
Journal Year:
2024,
Volume and Issue:
45(13), P. 1116 - 1124
Published: Feb. 7, 2024
Transcatheter
aortic
valve
implantation
(TAVI)
has
become
a
viable
treatment
option
for
patients
with
severe
stenosis
across
broad
range
of
surgical
risk.
The
Nordic
Aortic
Valve
Intervention
(NOTION)
trial
was
the
first
to
randomize
at
lower
risk
TAVI
or
replacement
(SAVR).
aim
present
study
report
clinical
and
bioprosthesis
outcomes
after
10
years.
European Heart Journal,
Journal Year:
2024,
Volume and Issue:
45(37), P. 3804 - 3814
Published: May 15, 2024
Transcatheter
aortic
valve
implantation
(TAVI)
has
become
the
first
choice
to
treat
older
patients
with
severe
symptomatic
stenosis
(AS).
This
study
aimed
compare
TAVI
surgery
in
low-risk
≤75
years
of
age,
including
both
tricuspid
and
bicuspid
AS.
Circulation,
Journal Year:
2023,
Volume and Issue:
149(9), P. 644 - 655
Published: Oct. 26, 2023
The
optimal
treatment
in
patients
with
severe
aortic
stenosis
and
small
annulus
(SAA)
remains
to
be
determined.
This
study
aimed
compare
the
hemodynamic
clinical
outcomes
between
transcatheter
valve
replacement
(TAVR)
surgical
(SAVR)
a
SAA.
Cardiovascular revascularization medicine,
Journal Year:
2024,
Volume and Issue:
65, P. 25 - 31
Published: March 7, 2024
Transcatheter
aortic
valve
replacement
(TAVR)
is
increasingly
performed
for
the
treatment
of
stenosis.
Computed
tomography
(CT)
analysis
essential
pre-procedural
planning.
Currently
available
software
packages
TAVR
planning
require
substantial
human
interaction.
We
describe
development
and
validation
an
artificial
intelligence
(AI)
powered
to
automatically
rend
anatomical
measurements
other
information
required
implantation.
Open Heart,
Journal Year:
2025,
Volume and Issue:
12(1), P. e003019 - e003019
Published: Jan. 1, 2025
Transcatheter
aortic
valve
replacement
(TAVR)
is
increasingly
used
for
instead
of
surgical
(sAVR).
We
aimed
to
examine
the
impact
diabetes
on
30-day
mortality,
readmission
and
compare
outcomes
between
TAVR
sAVR.
Data
were
extracted
from
Nationwide
Readmissions
Database
2012
2017.
The
primary
outcome
was
secondary
readmission.
study
included
110
135
patients
who
underwent
replacement.
Of
these,
59
466
(54.0%)
hospitalised
TAVR,
50
669
(46.0%)
Diabetes
present
in
36.4%
29.1%
sAVR
patients.
In
patients,
adjusted
risk
mortality
similar
regardless
status
(aHR=0.94
(0.86-1.03);
0.97
(0.84-1.12);
respectively).
However,
with
had
a
higher
(aHR=1.13
(1.01-1.25))
but
not
(aHR=0.92
(0.84-1.01)).
When
comparing
diabetes,
older
prevalence
chronic
kidney
disease
(CKD).
Nevertheless,
lower
(aHR=0.59
(0.53-0.67),
aHR=0.29
(0.25-0.34),
respectively)
compared
Coronary
artery
most
significant
predictor
diabetes.
CKD
increased
by
almost
twofold
both
techniques.
increases
short-term
TAVR.
Moreover,
incidence
among
КАРДИОЛОГИЯ УЗБЕКИСТАНА,
Journal Year:
2025,
Volume and Issue:
18(1), P. 103 - 115
Published: Jan. 1, 2025
Lifetime
treatment
of
aortic
valve
disease
is
a
matter
increasing
debate.
Although
the
risks
second
intervention
are
recognized,
little
attention
has
been
given
to
challenges
third.
This
study
delves
into
clinical
characteristics,
indications,
and
outcomes
patients
undergoing
3
interventions.
The
THIRD
(THree
aortIc
Reinterventions
for
Disease)
registry
retrospective
multicenter,
international
who
underwent
third
procedure
on
valve,
either
surgically
or
transcatheter-based.
Patients
2
procedures
during
same
hospital
admission
were
excluded.
Baseline
timing,
mode
bioprosthetic
failure,
sequence
procedures,
adjudicated
according
Valve
Academic
Research
Consortium
criteria.
A
total
51
from
11
centers
enrolled
in
this
study.
Median
follow-up
time
was
565
(314-1,560)
days.
Eighteen
(35%)
surgical
replacement
(SAVR),
33
(65%)
transcatheter
(TAVR)
as
intervention.
Mean
age
69
±
14
years,
20
(39%)
female.
STS
score
5.0%
(Q1-Q3:
3.3%-7.0%).
In
all
TAVR
cases,
indication
first
severe
stenosis,
31
45
(69%)
SAVR
cases
(33%
bicuspid).
most
prevalent
SAVR-SAVR-TAVR
(19/51,
37%),
followed
by
SAVR-SAVR-SAVR
(10/51,
20%)
SAVR-TAVR-TAVR
20%).
TAVR-TAVR-TAVR
performed
4
(8%).
primary
indications
included
structural
deterioration
(SVD)
(39/51,
76%),
non-SVD
(8/51,
16%),
endocarditis
(2/51,
4%).
Excluding
with
mechanical
prosthesis,
predictors
lower
(OR:
0.58;
95%
CI:
0.34-0.98;
P
=
0.04)
presence
moderate
prosthesis-patient
mismatch
44.8;
2.41-122.00;
0.01).
Thirty-day
device
success
85%
94%
SAVR.
registry,
SVD
emerged
predominant
procedure.
frequent
SAVR-SAVR-TAVR,
whereas
less
common.
short-term
our
selected
cohort
favorable,
further
investigation
needed.
